FibroGen Inc (FGEN) Company Profile & Statistics

FibroGen Inc
FGEN
(Nasdaq - US)
N/A
1.16
+0.02 (+1.75%)
in:usd•As of: May 06, 2024 15:59 UTC -4
After Market:1.39+0.23 (+19.83%)
Open
1.21
High
1.26
Low
1.15

About FibroGen Inc

CEO

Thane Wettig

Headquarters

409 illinois street

san francisco, ca 94158, united states

Auditor

PricewaterhouseCoopers LLP

Employees

486

Share Holders

105

Website

www.fibrogen.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

FibroGen Inc Statistics

Valuation Measures

Market Capitalization ²	115.39M
Enterprise Value	73.63M
Enterprise Value/EBITDA (ttm)	-0.27
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	0.77
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	86.74%
Operating Margin (ttm)	-167.19%
Profit Margin (ttm)	-193.92%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	1258.50%
Return on Assets (ttm)	-51.00%

Income Statement

Revenue (ttm)	147.75M
Revenue Per Share (ttm)	1.50
Gross Profit (ttm)	128.90M
EBITDA (ttm)³	-276.95M
Net Income Avi to Common (ttm)	-284.23M
Diluted EPS (ttm)	-2.93

Share Statistics

Beta (5Y Monthly)	0.88
52-Week Change	-93.47%
S&P500 52-Week Change	27.73%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	98.77M
Dividend Yield	0.00%
Float ⁴	97.50M
% Held by Insiders	1.98%
% Held by Institutions	72.71%

Balance Sheet

Total Cash (mrq)	235.59M
Total Cash Per Share (mrq)	2.39
Total Debt (mrq)	71.93M
Total Debt/Equity (mrq)	-39.16%
Current Ratio (mrq)	1.52%
Quick Ratio (mrq)	1.33%
Book Value Per Share (mrq)	-1.86

Cash Flow

Operating Cash Flow Per Share (ytd)	-3.24
Free Cash Flow (ytd)	-317.54M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

FibroGen Inc

Trade With A Regulated Broker